Skip to main content
Clinical Trials/NCT05827250
NCT05827250
Recruiting
Not Applicable

Passive Infrasound-to-ultrasound Vibrome Biosignatures of Lung Development in Newborn Infants

Level 42 AI, Inc.1 site in 1 country200 target enrollmentFebruary 13, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prematurity
Sponsor
Level 42 AI, Inc.
Enrollment
200
Locations
1
Primary Endpoint
Gestational age change in lung vibroacoustics
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Investigators hypothesize that premature newborns with poor cardiopulmonary performance have higher morbidities and poorer physical and cognitive developmental outcomes.

Investigators further hypothesize that audible sounds combined with novel inaudible vibrations above and below human perception interpreted with transparent and auditable AI algorithms can detect and identify early gas and fluid movement anomalies not uncovered by conventional tools in an non-invasive, easy, fast, and low cost examination.

Detailed Description

Worldwide preterm birth (\<37 weeks of gestation) affects approximately 10% of live births and is the leading cause of death in children less than 5 years of age. Preterm birth disrupts normal lung development leading to several respiratory complications in the neonatal period and later in life. Consequently, factors that negatively affect prenatal and early life respiratory growth can compromise the achievement of "personal-best lung function". This novel study will generate normative, audible/inaudible frequencies, visible/invisible frequencies, and perceptible/imperceptible energies, termed vibrome biosignatures, of cardiopulmonary development and function during early postnatal development. Once baseline patterns are established, future studies will be designed to characterize vibrome biosignature differences across acute neonatal respiratory problems, such as respiratory distress syndrome, meconium aspiration, sepsis, persistent pulmonary hypertension, and congenital heart disease.

Registry
clinicaltrials.gov
Start Date
February 13, 2023
End Date
February 28, 2025
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Eligible participants include all infants admitted to the NICU.

Exclusion Criteria

  • There are no exclusions to enrollment in this study.

Outcomes

Primary Outcomes

Gestational age change in lung vibroacoustics

Time Frame: through study completion, an average of 6 weeks

Correlate the relationship of vibroacoustic measurements (i.e., vibroacoustic wave's maximum pressure fluctuations, represented by the base unit known as a Pascal) with gestational age (wks) as modified by clinical status.

Study Sites (1)

Loading locations...

Similar Trials